title: [Novel strategies for the development of anabolic agents for treatment of osteoporosis].
authors.forename: Makio
authors.initials: M
authors.lastname: Saeki
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Egusa
mesh_terms: D045930:Anabolic Agents; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use; D001552:Benzazepines; D001713:Biphenyl Compounds / Q000494:pharmacology / Q000627:therapeutic use; D050071:Bone Density Conservation Agents; D016723:Bone Remodeling / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects; D000069448:Denosumab; D055808:Drug Discovery / Q000639:trends*; D004353:Drug Evaluation, Preclinical; D006247:Harmine / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007211:Indoles; D018020:Lithium Compounds / Q000008:administration & dosage / Q000494:pharmacology; D058990:Molecular Targeted Therapy; D050778:NFATC Transcription Factors; D010006:Osteoblasts / Q000166:cytology; D010010:Osteoclasts / Q000166:cytology; D010012:Osteogenesis / Q000187:drug effects; D010024:Osteoporosis / Q000188:drug therapy* / Q000235:genetics; D010281:Parathyroid Hormone / Q000008:administration & dosage / Q000494:pharmacology; D019379:Teriparatide / Q000008:administration & dosage / Q000494:pharmacology; D060449:Wnt Signaling Pathway / Q000235:genetics / Q000502:physiology
chemical_list: D045930:Anabolic Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001552:Benzazepines; D001713:Biphenyl Compounds; D050071:Bone Density Conservation Agents; D007211:Indoles; D018020:Lithium Compounds; D050778:NFATC Transcription Factors; D010281:Parathyroid Hormone; C119620:kenpaullone; D019379:Teriparatide; C557282:romosozumab; D000069448:Denosumab; D006247:Harmine; C527128:odanacatib